Epidermal growth factor receptor protein expression in lung cancer and survival analysis

Salimath, Shivalingaswamy; B. S., Jayaraj; P. A., Mahesh; Pasha, M. D. Majeed; K. S., Lokesh; M., Mahendra.
Artículo | IMSEAR | ID: sea-193975

Documentos relacionados

  1. Endobronchial Ultrasound Guided Transbronchial Needle Aspiration and PD-L1 Yields.
  2. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
  3. A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma.
  4. Therapeutic impact of epidermal growth factor receptor tyrosine kinase inhibitor with various treatment combinations for advanced lung adenocarcinoma.
  5. Prediction model on disease recurrence for low risk resected stage I lung adenocarcinoma.
  6. Effect of initial recurrence site on the prognosis of different tissue types of non-small cell lung cancer: a retrospective cohort study.
  7. A novel nomogram for identifying candidates for adjuvant chemotherapy in patients with stage IB gastric adenocarcinoma.
  8. ALK rearrangements in EBUS-derived transbronchial needle aspiration cytology in lung cancer.
  9. Five-year survival of resectable stage IIIA non-small cell lung cancer in Brazil.
  10. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study.